Egetis Therapeutics
Develops and commercializes treatments for serious and rare diseases.
EGTX | ST
Overview
Corporate Details
- ISIN(s):
- SE0003815604
- LEI:
- 549300RZCKGWRUBPMY22
- Country:
- Sweden
- Address:
- Klara Norra Kyrkogata 26, 111 22 Stockholm
- Website:
- https://www.egetis.com/
- Sector:
- Manufacturing
Description
Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-09-30 17:31 |
Egetis Therapeutics announces the intention to carry out directed share issuanc…
|
English | 85.0 KB | ||
| 2024-08-22 07:00 | Swedish | 4.6 MB | |||
| 2024-08-22 07:00 | English | 4.1 MB | |||
| 2024-06-19 18:50 |
Egetis rapporterar topline-resultat från fas 2 studien Triac Trial II med Emcit…
|
Swedish | 83.0 KB | ||
| 2024-06-19 18:50 |
Egetis announces topline results of the Phase 2 Triac Trial II with Emcitate® (…
|
English | 85.3 KB | ||
| 2024-05-23 00:00 | Swedish | 23.8 MB | |||
| 2024-05-06 18:53 |
Bulletin from Egetis Therapeutics’ Annual General Meeting 2024
|
English | 57.8 KB | ||
| 2024-05-06 18:53 |
Kommuniké från Egetis Therapeutics årsstämma 2024
|
Swedish | 60.7 KB | ||
| 2024-05-03 07:00 | Swedish | 4.2 MB | |||
| 2024-05-03 07:00 | English | 3.6 MB | |||
| 2024-04-24 12:15 |
Valberedningen justerar sitt förslag inför årsstämman i Egetis Therapeutics AB …
|
Swedish | 42.1 KB | ||
| 2024-04-24 12:15 |
The Nomination Committee adjusts its proposal for the annual general meeting of…
|
English | 37.0 KB | ||
| 2024-04-15 14:35 | Swedish | 13.2 MB | |||
| 2024-04-15 14:35 | Swedish | 13.2 MB | |||
| 2024-03-29 18:38 |
KALLELSE TILL ÅRSSTÄMMA I EGETIS THERAPEUTICS AB (PUBL)
|
Swedish | 120.6 KB |
Automate Your Workflow. Get a real-time feed of all Egetis Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Egetis Therapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Egetis Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-09 | Yilmaz Mahshid | Other | Sell | 39,753 | 268,332.75 SEK |
| 2025-01-08 | Yilmaz Mahshid | Other | Sell | 98,567 | 653,499.21 SEK |
| 2025-01-07 | Yilmaz Mahshid | Other | Sell | 74,769 | 507,681.51 SEK |
| 2024-10-07 | Nicklas Westerholm | Other | Buy | 10,142 | 43,103.50 SEK |
| 2024-10-07 | Yilmaz Mahshid | Other | Buy | 10,000 | 42,250.00 SEK |
| 2023-07-07 | Henrik Krook | Other | Buy | 33,594 | 133,704.12 SEK |
| 2023-07-06 | Christian Sonesson | Other | Buy | 3,616 | 14,391.68 SEK |
| 2023-07-06 | Christian Sonesson | Other | Buy | 2,000 | 7,920.00 SEK |
| 2023-07-05 | Christian Sonesson | Other | Buy | 1,384 | 5,452.96 SEK |
| 2023-07-04 | Nicklas Westerholm | Other | Buy | 15,350 | 60,632.50 SEK |
Peer Companies
